1. correlation between COVID-19 and Hypertension and/or kidney diseases.
2. Assess Assess the effect of COVID-19 on patients with Hypertension and/or kidney diseases.
3. Assess the effect of hypertension and/or kidney diseases on COVID-19 presentation.
4. Assess the outcome of COVID-19 in patients with hypertension and/or kidney diseases

The pandemic situation with the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from China has endangered human lives. Coronavirus disease 2019 (COVID-19) is presented with asymptomatic, mild, or severe pneumonia-like symptoms¹.SARS-CoV-2 has infected humans in all age groups, of all ethnicities, both males and females while spreading through communities at an alarming rate². COVID-19 patients with hypertension, chronic kidney disease, Diabetes, malignancies, HIV, and other comorbidities could develop a life-threatening situation. From the data have reported the characteristics of comorbidities in patients with COVID-19, hypertension was present in nearly 21%, followed by diabetes in nearly 11%, and established cardiovascular disease (CVD) in approximately 7% of patients³.

Hypertension posed an increased risk of severe morbidity (approx. 4-fold) and death (approx. 7-fold) from COVID-19 in the presence of multiple comorbidities⁴.

The patients with underlying kidney problems are vulnerable to developing COVID-19 infection.The disease also has had consequences on longitudinal management of patients with chronic kidney disease and end stage kidney disease.

Inclusion Criteria:

Patients above 18 years old. Patients who diagnosed as COVID-19 PCR positive with hypertension and/or kidney diseases.

Exclusion Criteria:

Young patients below 18 years old. Patients who refused to participate in reseach

Patients admitted to ICU with positive PCR with Hypertension and/or kidney diseases.